44 results about "Skeletal muscle atrophy" patented technology

The invention relates to the field of muscle pathologies, more particularly to the field of diseases where skeletal muscle degeneration occurs. The invention describes transgenic mice that do not produce prolyl-hydroxylase-1, -2 or -3. It is revealed that the phenotype of the prolyl-hydroxylase 1 knock-out mouse is characterized by a protection of skeletal muscle atrophy due to a variety of muscle damages, especially ischemic insults. The invention thus relates to the use of molecules that can bind to prolyl-hydroxylase-1 for the prevention and / or treatment of skeletal muscle degeneration.

The invention provides a flavonoids compound, a preparation method and an application of the flavonoids compound in medicine for prevention and treatment of cachexia. The compound has a structure shown in a structural formula (I) as follows. The provided flavonoids compound can be used for preparing the medicine for treating human and animal cachexia, and cachexia relative to a plurality of diseases can be treated, lowered body weight due to skeletal muscle atrophy and fat degradation atrophy can be effectively alleviated, tumour burden can be obviously mitigated, protein degradation is inhibited, and cytokine TNF-a and IL-6 level can be increased.

The present invention discloses a filtering method of identifying compound which is used to or activate (D1 or D5 dopamine receptor, sole or combined) or regulate or potentially regulate skeletal muscle quality or function in human body. The present invention also discloses a filtering method of identifying compound which is used to prolong or increase D1 or D5 dopamine receptor or its signal transduction pathways and to increase D1 or D5 dopamine receptor expression. The present invention describes a drug compound containing D1 or D5 dopamine receptor agonist, and D1 or D5 dopamine receptor antibody, and a method for enhancing skeletal muscle quality or function, or for treating skeletal muscle atrophy using D1 or D5 dopamine receptor as intervention target, as well as a method for treating skeletal muscle atrophy.

Screening methods for identifying compounds that bind to or activate corticotropin releasing factor2 receptors (CRF2R) and regulate or potentially regulate skeletal muscle mass or function in vivo are disclosed. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of CRF2Rs or of CRF2R signal transduction pathways, increase CRF2R or increase CRF expression are provided. Pharmaceutical compositions comprising CRF2R agonists, antibodies to CRF2R and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using CRF2R as the target for intervention and methods for treatment of muscular dystrophies are described.

The invention discloses a CD29<+> human umbilical cord source mesenchymal stem cell and use thereof in the preparation of a drug for treating skeletal muscle atrophy in high-sugar and high-fat environments. The CD29<+> human umbilical cord source mesenchymal stem cell represents the following mesenchymal stem cell cytomembrane molecules: a human leukocyte differentiation antigen CD73, a human leukocyte differentiation antigen CD90, a human leukocyte differentiation antigen CD105 and a human leukocyte differentiation antigen CD29. According to the CD29<+> human umbilical cord source mesenchymalstem cell, the hyperlipidemia and hyperglycemia of a db<- / -> mouse can be obviously improved, muscle fiber cross sections of soleus and gastrocnemius muscle of the db<- / -> mouse can be increased, andthe contents and cell number of each myotube are increased, so that the symptoms of the skeletal muscle atrophy of the db<- / -> mouse are improved. According to the CD29<+> human umbilical cord sourcemesenchymal stem cell, the theoretical foundation and experiment basis are laid for the subsequent research and development of the drug for treating skeletal muscle atrophy in the high-sugar and high-fat environments, and the CD29<+> human umbilical cord source mesenchymal stem cell has wide application prospects.

The invention provides a circuit control device and a vibrator based on muscle vibration. Wherein, the circuit control device includes: a multivibrator, the multivibrator includes a frequency adjustment switch, based on the 555 timer circuit, the frequency adjustment is realized by changing the resistance value of a plurality of resistors, and is used to adjust the above-mentioned multivibrator Transducers are capable of operating at several different frequencies. The invention solves the problem that the working frequency of the equipment used for muscle vibration training in the related art is relatively single and cannot adapt to the training needs of different parts, improves the practicability of vibration training, and can effectively meet the needs of skeletal muscles caused by long-term braking such as paralysis. Prevention of atrophy and skeletal muscle loss in aging.

The present invention provides methods for the treatment of denervation-induced skeletal muscle atrophy, and generally, denervation-induced skeletal muscle degeneration diseases using agents that decrease the activity of mammalian target of rapamycin and / or the activity of at least one of the Forkhead Box Transcription Factors 1, 3 and 4.

The present invention relates to ALK5 inhibitors and their uses as skeletal muscle hypertrophy inducers as well as to promote skeletal muscle regeneration, to prevent skeletal muscle atrophy, or in the treatment or prevention of a disease or injury resulting in loss of skeletal muscle tissue and / or muscle weakness. It further relates to the non-therapeutic use of such compounds to increase musclemass, muscle strength and / or muscle performance in a subject.

The invention relates to a method for determining whether a compound is a neurotrypsin inhibitor, characterized in that the compound is incubated together with neurotrypsin, a variant thereof or a fragment comprising the protease domain and with a protein or peptide comprising agrin, a variant thereof or a fragment comprising the α- or the β-cleavage site of agrin, in an aqueous buffer solution, and the amount of cleavage of agrin is measured. Additionally, the invention relates to inhibitors of neurotrypsin found by this method, in particular to compounds of formulawherein Hal1 and Hal2 are fluorine, chlorine or bromine, and the use of such inhibitors for the treatment and / or prophylaxis of diseases caused by deficiency of synapses, for example skeletal muscle atrophy, schizophrenia, and cognitive disturbance.

The invention discloses a CD29<+> human umbilical cord source mesenchymal stem cell and use thereof in the preparation of a drug for treating skeletal muscle atrophy in high-sugar and high-fat environments. The CD29<+> human umbilical cord source mesenchymal stem cell represents the following mesenchymal stem cell cytomembrane molecules: a human leukocyte differentiation antigen CD73, a human leukocyte differentiation antigen CD90, a human leukocyte differentiation antigen CD105 and a human leukocyte differentiation antigen CD29. According to the CD29<+> human umbilical cord source mesenchymalstem cell, the hyperlipidemia and hyperglycemia of a db<- / -> mouse can be obviously improved, muscle fiber cross sections of soleus and gastrocnemius muscle of the db<- / -> mouse can be increased, andthe contents and cell number of each myotube are increased, so that the symptoms of the skeletal muscle atrophy of the db<- / -> mouse are improved. According to the CD29<+> human umbilical cord sourcemesenchymal stem cell, the theoretical foundation and experiment basis are laid for the subsequent research and development of the drug for treating skeletal muscle atrophy in the high-sugar and high-fat environments, and the CD29<+> human umbilical cord source mesenchymal stem cell has wide application prospects.

The invention discloses a portable sitting and standing function evaluation and training device which is connected with an upper computer through wireless communication and mainly comprises a pedal module and a cushion module, wherein a power module, a CPU (central processing unit), a foot sole pressure sensor and a Bluetooth module are arranged in the pedal module; a hip pressure sensor is arranged in the cushion module; the foot sole pressure sensor is used for collecting pressure signals of left and right feet; the hip pressure sensor is used for collecting pressure signals of left and right hips; and the CPU is used for processing the pressure signals of the hips and the foot soles and communicates with the upper computer through the Bluetooth module. The sitting and standing functions of a patient are evaluated and trained through sitting and standing function evaluation and training software arranged in the upper computer. The portable sitting and standing function evaluation and training device has the advantages of low power consumption, small volume, convenience for carrying and the like, achieves wireless communication by the Bluetooth module without signal connection wires or cables, is convenient to operate, and can be widely applied to biomedical instruments for treating diseases such as skeletal muscle atrophy, nerve injury, paralysis and the like.